LB Pharmaceuticals Inc: H.C. Wainwright raises target price to $60 from $45

H.C. Wainwright & Co. has revised its price target for LB Pharmaceuticals Inc (NASDAQ: LBPH), raising it to $60 from $45, reflecting a positive reassessment of the company’s outlook. The adjustment follows recent developments in the company’s pipeline and strategic initiatives, which the firm believes position LB Pharmaceuticals for stronger performance in the near term. The updated target suggests increased confidence in the stock’s potential, though it does not constitute a recommendation to buy or sell. Investors are advised to consider broader market conditions and company-specific risks when evaluating their positions. The firm’s analysis is based on current financial and operational data, and any future changes in the company’s performance or market dynamics could influence its valuation. As with all investment decisions, due diligence and consultation with a financial advisor are recommended.